The Application of a Novel Urinalysis System (UF-5000) for Reducing Unnecessary Antibiotic Use in Clinical Suspected UTI Patients

October 29, 2026 updated by: Yung NA, The University of Hong Kong

Urinary tract infection (UTI) is one of the most common diseases in the population, while antibiotic resistance in UTI has become a critical problem in Hong Kong, with a large proportion of bacteria causing UTI resistant to commonly used anti-UTI antibiotic treatments. This resistance is largely due to empirical treatment (i.e. no bacterial information is available at the time of treatment) and antibiotic overtreatment over the past decades. Some patients without UTI were prescribed antibiotics because of symptoms similar to UTI.

To avoid unnecessary antibiotic use and therefore reduce antibiotic resistance rates in UTI, the investigators propose to apply a new urine sediment analyzer (UF-5000) in clinical practice for UTI. The analyzer could provide rapid identification of potential bacteria in urine and more information on possible bacterial species. UF-5000 is a urine sediment analyzer manufactured by Sysmex Ltd. (Japan). The analyzer is widely used in hospital central laboratories and private laboratories but is not commonly seen in outpatient clinic settings. UF-5000 is capable of counting bacteria present in a urine sample and providing Gram staining results within 5 minutes, while routine urine culture takes around 3 days.

A study conducted by The University of Hong Kong in 2019 showed that UF-5000 has higher accuracy than conventional dipstick testing, with reliable Gram staining results. The analyzer has a negative predictive value of 96%, indicating a high likelihood that a negative result corresponds to the absence of UTI. Cases with symptoms similar to UTI were mostly inflammatory diseases without a need for antibiotics.

This study aims to evaluate whether bacterial information provided by UF-5000 can guide precise antibiotic treatment and avoid unnecessary antibiotic use.

Study Overview

Study Type

Interventional

Enrollment (Actual)

198

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Hong Kong
      • Hong Kong, Hong Kong, Hong Kong
        • Queen Mary Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 99 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  1. Adult patients who are suspected to have LUTs in outpatient clinic.
  2. Willing to consent to participate the trial.
  3. Be able to understand the nature of the study.

Exclusion Criteria:

  1. Any suspected or known sexual transmitted diseases. (Such as gonorrhea, etc.)
  2. Use of any systematic antibiotics or antiviral treatment within two weeks
  3. With evidence of systematic infection including high fever, significantly increase of blood white blood cell count, etc.
  4. Known or suspected allergic history/adverse drug reactions to any antibiotics
  5. With previous history of multidrug resistant (MDR) bacterial infection.
  6. Any medical history that indicates the need of immediate antibiotics treatment, such as chronic conditions and/or taking immunosuppressants.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Diagnostic
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: Control Arm

Empirical antibiotics, including amoxicillin/clavulanate (Augmentin), cefuroxime, ciprofloxacin, levofloxacin, and nitrofurantoin, without bacterial information.

Empirical antibiotics, including amoxicillin/clavulanate (Augmentin), cefuroxime, ciprofloxacin, levofloxacin, and nitrofurantoin, per local guidelines and/or the investigator's discretion for urinary tract infection.

Experimental: Experimental Arm

Antibiotics prescription with reference from study device. High bacterial count suggests likelihood of active UTI and indicated for antibiotics treatment; while low bacterial count suggests UTI not likely and antibiotics treatment will be delayed until urinary culture result confirms ongoing UTI.

Provide real time bacterial count in urine samples and Gram-staining results. High bacterial count suggests likelihood of active UTI and indicated for antibiotics treatment; while low bacterial count suggests UTI not likely.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Proportion of subjects assigned with "Delay antibiotics treatment" in the intervention group that has confirmed no clinical indication for antibiotics treatment
Time Frame: 1 week

The rate of unnecessary antibiotics use avoided in the intervention group. Defined as proportion of subjects assigned with "Delay antibiotics treatment" as indicated by low real-time bacterial count in urine that had negative or clinically insignificant urine culture result in one week.

1 week

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Number of subjects achieved urinary sterility after antibiotics treatment in confirmatory urine test
Time Frame: 1 week

Defined as negative white blood cell in urine dipstick and no growth in urine culture. Only applies to subjects that have finished a course of antibiotics treatment under study setting.

1 week
Number of participants that persist to have baseline lower tract urinary symptoms as assessed in CTCAE 4.0
Time Frame: 1 week

The symptoms would be assessed through phone follow-up.

1 week
Number of participants with antibiotics treatment-related adverse events as assessed by CTCAE v4.0
Time Frame: 2 weeks

The symptoms would be assessed through phone follow-up.

2 weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

November 6, 2023

Primary Completion (Actual)

December 31, 2025

Study Completion (Actual)

February 28, 2026

Study Registration Dates

First Submitted

May 7, 2024

First Submitted That Met QC Criteria

April 1, 2025

First Posted (Actual)

April 9, 2025

Study Record Updates

Last Update Posted (Actual)

November 3, 2026

Last Update Submitted That Met QC Criteria

October 29, 2026

Last Verified

October 1, 2026

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe